Prevention of ventricular arrhythmias in the congenital long QT syndrome

被引：20

作者：

Viskin S. ^{[1
]}

Fish R. ^{[1
]}

机构：

[1] Department of Cardiology, Sourasky-Tel Aviv Medical Center, Tel Aviv University, Tel Aviv 64239

来源：

Current Cardiology Reports | 2000年 / 2卷 / 6期

关键词：

Flecainide; Nicorandil; Tocainide; Blocker Therapy; Cardiac Pace;

D O I：

10.1007/s11886-000-0033-2

中图分类号：

学科分类号：

摘要：

Life-long therapy is necessary for patients with symptomatic long QT syndrome to prevent arrhythmic death. The merits and limitations of the different therapeutic modalities are discussed. b-blockers remain the mainstay of therapy, but this medication may not be sufficient for cardiac arrest survivors and for those with the LQT3 genotype. "Genotype-specific" therapy, like potassium-channel openers for patients with inadequate potassium outflow (LQT1 and LQT2 genotypes) or sodium-channel blockers for patients with excessive sodium inflow (LQT3), significantly shortens the QT interval, but the effects of these drugs on arrhythmia prevention is less well established. Cardiac pacemakers may be especially beneficial for patients with LQT2 or LQT3 and for those with pause-dependent torsade de pointes. More important is to recognize that device programming for preventing tachyarrhythmias in patients with long QT differs from the standard pacemaker programming. Finally, implantable defibrillators with dual-chamber pacing capability are indicated for patients at high risk for arrhythmic death, including all cardiac arrest survivors. Copyright © 2000 by Current Science Inc.

引用

页码：492 / 497

页数：5

共 48 条

[31]

Benhorin J., Taub R., Goldmit M., Et al., Effects of flecainide in patients with new SCN5A mutation. Mutation-specific therapy for long-QT syndrome?, Circulation, 101, pp. 1698-1706, (2000)

[32]

Compton S.J., Lux R.L., Ramsey M.R., Et al., Genetically defined therapy of inherited long QT syndrome. Correction of abnormal repolarization by potassium, Circulation, 94, pp. 1018-1022, (1996)

[33]

Choy A.M., Lang C.C., Chomsky D.M., Et al., Normalization of acquired QT prolongation in humans by intravenous potassium, Circulation, 97, pp. 2149-2154, (1997)

[34]

Yang T., Roden D.M., Extracellular potassium modulation of drug block of IKr: Implications for torsades de pointes and reverse use-dependence, Circulation, 93, pp. 407-411, (1996)

[35]

Tan H.L., Alings M., Van-Olden R.W., Aam W., Long-term (subacute) potassium treatment in congenital HERG-related long QT syndrome (LQTS2), J Cardiovasc Electrophysiol, 10, pp. 229-233, (1999)

[36]

Fujimoto Y., Morita H., Fukushima K.K., Ohe T., Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome, Heart, 82, (1999)

[37]

Chinushi M., Aizawa Y., Furushima H., Et al., Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome, Jpn Heart J, 36, pp. 477-481, (1995)

[38]

Sato T., Hata Y., Yamamoto M., Et al., Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome, J Cardiovasc Electrophysiol, 6, pp. 279-282, (1995)

[39]

Viskin S., Barron H.V., Olgin J., Heller K., Scheinman M.M., The treatment of atrial fibrillation: Pharmacologic and nonpharmacologic strategies, Curr Prob Cardiol, 22, pp. 37-108, (1997)

[40]

Rashba E.J., Zareba W., Moss A.J., Et al., Influence of pregnancy on the risk of cardiac events in patients with hereditary long QT syndrome, Circulation, 97, pp. 451-456, (1998)

← 1 2 3 4 5 →